384 653

Cited 13 times in

Dynamic risk stratification in medullary thyroid carcinoma: Single institution experiences

DC Field Value Language
dc.contributor.author강상욱-
dc.contributor.author남기현-
dc.contributor.author반은정-
dc.contributor.author이슬기-
dc.contributor.author이잔디-
dc.contributor.author이초록-
dc.contributor.author정웅윤-
dc.contributor.author정종주-
dc.contributor.author최정범-
dc.date.accessioned2019-01-15T17:11:27Z-
dc.date.available2019-01-15T17:11:27Z-
dc.date.issued2018-
dc.identifier.issn0025-7974-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/166853-
dc.description.abstractRecently, dynamic risk stratification has been found to be more valuable than static anatomic staging system in nonmedullary thyroid cancer and this strategy has also been accepted in medullary thyroid cancer (MTC). The present study was designed to compare the clinical usefulness of response to initial therapy stratification with a traditional anatomic staging system.From August 1982 to December 2012, a total of 144 MTC patients underwent thyroidectomy in Yonsei University Hospital. Among them, 117 (82.2%) patients with complete clinical data and sustained follow-up were enrolled in this study. Clinicopathological features and surgical outcomes were analyzed by retrospective medical chart review. Mean follow-up duration was 85.78 ± 62.51 months.In this study, mean tumor size was 1.94 ± 1.40 cm and 22 (18.9%) patients had hereditary MTC; 95 (81.1%) patients had sporadic MTC. Stage I patients had highest probability of excellent response to initial therapy (92.1%). Stage IV patients had highest probability of biochemical and structural incomplete response to initial therapy (57.5% and 30.3%) and lowest probability of excellent response to initial therapy (12.1%). Both response to initial therapy stratification and TNM staging system offered useful prognostic information in this study. The TNM staging system provided risk stratification pertaining to disease-free survival (DFS), disease-specific survival (DSS), and the probability of having no evidence of disease at final outcome, but did not provide risk stratification pertaining to the probability of having biochemical persistent/recurrence disease at final outcome. However, response to initial therapy stratification provided risk stratification pertaining to not only DFS, DSS, and the probability of having no evidence of disease at final outcome but also the probability of having biochemical persistent/recurrence disease at final outcome.In this study, we demonstrated that dynamic risk stratification with adjusted response to initial therapy system can offer more useful prognostic information than anatomic staging system in MTC.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherLippincott Williams & Wilkins-
dc.relation.isPartOfMEDICINE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHCarcinoma, Neuroendocrine/pathology-
dc.subject.MESHCarcinoma, Neuroendocrine/therapy*-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Staging-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHRisk Assessment-
dc.subject.MESHThyroid Neoplasms/pathology-
dc.subject.MESHThyroid Neoplasms/therapy*-
dc.subject.MESHTreatment Outcome-
dc.titleDynamic risk stratification in medullary thyroid carcinoma: Single institution experiences-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Surgery (외과학교실)-
dc.contributor.googleauthorJung Bum Choi-
dc.contributor.googleauthorSeul Gi Lee-
dc.contributor.googleauthorMin Jhi Kim-
dc.contributor.googleauthorTae Hyung Kim-
dc.contributor.googleauthorEun Jeong Ban-
dc.contributor.googleauthorCho Rok Lee-
dc.contributor.googleauthorJandee Lee-
dc.contributor.googleauthorSang-Wook Kang-
dc.contributor.googleauthorJong Ju Jeong-
dc.contributor.googleauthorKee-Hyun Nam-
dc.contributor.googleauthorWoong Youn Chung-
dc.identifier.doi10.1097/MD.0000000000009686-
dc.contributor.localIdA00032-
dc.contributor.localIdA01245-
dc.contributor.localIdA01782-
dc.contributor.localIdA02909-
dc.contributor.localIdA03066-
dc.contributor.localIdA03256-
dc.contributor.localIdA03674-
dc.contributor.localIdA03722-
dc.contributor.localIdA04696-
dc.relation.journalcodeJ02214-
dc.identifier.eissn1536-5964-
dc.identifier.pmid29505021-
dc.contributor.alternativeNameKang, Sang Wook-
dc.contributor.affiliatedAuthor강상욱-
dc.contributor.affiliatedAuthor남기현-
dc.contributor.affiliatedAuthor반은정-
dc.contributor.affiliatedAuthor이슬기-
dc.contributor.affiliatedAuthor이잔디-
dc.contributor.affiliatedAuthor이초록-
dc.contributor.affiliatedAuthor정웅윤-
dc.contributor.affiliatedAuthor정종주-
dc.contributor.affiliatedAuthor최정범-
dc.citation.volume97-
dc.citation.number3-
dc.citation.startPagee9686-
dc.identifier.bibliographicCitationMEDICINE, Vol.97(3) : e9686, 2018-
dc.identifier.rimsid58224-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Yonsei Biomedical Research Center (연세의생명연구원) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.